Researchers have identified a set of genetic abnormalities that can enhance prognostic accuracy and aid treatment selection for people with acute myelogenous leukemia (AML).

Findings from a multidisciplinary research team led by Memorial Sloan-Kettering medical oncologist and immunologist Jedd Wolchok could help shed light on the immune system’s role in fighting cancer.

The recent FDA approval of axitinib provides a viable treatment option for patients who progress on or cannot tolerate the side effects of other approved drugs for the disease.

The success of an experimental prostate cancer treatment is an example of how academic research centers are playing a larger role in drug development, the Wall Street Journal reports.

Breast Surgical Service Chief Monica Morrow provides perspective on assessing the quality of surgical breast cancer treatment in an editorial in the February 1 issue of the Journal of the American Medical Association.

Our ovarian cancer nomogram is a personalized tool that can help you and your doctor make important treatment decisions after surgery.

The Spine Tumor Center at Memorial Sloan-Kettering provides state-of-the-art diagnostic and treatment services for more than 1,500 people with primary or metastatic spine tumors each year.